Federal Register Notice: FDA is making available a revised draft guidance for industry on lamotrigine extended-release tablets entitled Draft Guidance on Lamotrigine. The recommendations provide specific guidance on the design of bioequivalence studies to support ANDAs for lamotrigine extended-release tablets. To view this notice, click here.
